Intrinsic value of RedHill Biopharma ADR - RDHL

Previous Close

$8.09

  Intrinsic Value

$0.47

stock screener

  Rating & Target

str. sell

-94%

Previous close

$8.09

 
Intrinsic value

$0.47

 
Up/down potential

-94%

 
Rating

str. sell

We calculate the intrinsic value of RDHL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  6
  10
  15
  21
  30
  42
  56
  73
  95
  119
  148
  181
  219
  260
  306
  356
  410
  468
  530
  596
  665
  738
  815
  896
  980
  1,068
  1,159
  1,254
  1,353
  1,455
Variable operating expenses, $m
  389
  601
  898
  1,303
  1,839
  2,528
  3,393
  4,455
  5,732
  7,240
  8,989
  10,990
  13,247
  15,761
  18,532
  21,558
  24,833
  28,352
  32,110
  36,101
  40,320
  44,763
  49,425
  54,306
  59,404
  64,720
  70,255
  76,015
  82,004
  88,228
Fixed operating expenses, $m
  27
  27
  28
  28
  29
  30
  30
  31
  32
  32
  33
  34
  35
  35
  36
  37
  38
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
Total operating expenses, $m
  416
  628
  926
  1,331
  1,868
  2,558
  3,423
  4,486
  5,764
  7,272
  9,022
  11,024
  13,282
  15,796
  18,568
  21,595
  24,871
  28,390
  32,149
  36,141
  40,361
  44,805
  49,468
  54,350
  59,449
  64,766
  70,302
  76,063
  82,053
  88,278
Operating income, $m
  -409
  -618
  -911
  -1,310
  -1,837
  -2,516
  -3,367
  -4,412
  -5,669
  -7,152
  -8,874
  -10,843
  -13,063
  -15,536
  -18,263
  -21,239
  -24,461
  -27,923
  -31,620
  -35,546
  -39,696
  -44,066
  -48,653
  -53,454
  -58,469
  -63,698
  -69,143
  -74,809
  -80,700
  -86,823
EBITDA, $m
  -409
  -617
  -911
  -1,309
  -1,836
  -2,514
  -3,365
  -4,410
  -5,666
  -7,149
  -8,870
  -10,838
  -13,057
  -15,530
  -18,255
  -21,230
  -24,450
  -27,911
  -31,606
  -35,531
  -39,679
  -44,048
  -48,632
  -53,431
  -58,444
  -63,671
  -69,114
  -74,777
  -80,666
  -86,786
Interest expense (income), $m
  0
  0
  0
  1
  2
  3
  4
  6
  9
  12
  15
  19
  24
  29
  36
  43
  50
  58
  67
  77
  87
  98
  110
  122
  135
  148
  162
  177
  192
  208
  224
Earnings before tax, $m
  -409
  -619
  -912
  -1,312
  -1,840
  -2,520
  -3,373
  -4,421
  -5,680
  -7,168
  -8,893
  -10,867
  -13,092
  -15,572
  -18,305
  -21,289
  -24,519
  -27,990
  -31,697
  -35,633
  -39,794
  -44,176
  -48,775
  -53,589
  -58,617
  -63,860
  -69,320
  -75,001
  -80,907
  -87,047
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -409
  -619
  -912
  -1,312
  -1,840
  -2,520
  -3,373
  -4,421
  -5,680
  -7,168
  -8,893
  -10,867
  -13,092
  -15,572
  -18,305
  -21,289
  -24,519
  -27,990
  -31,697
  -35,633
  -39,794
  -44,176
  -48,775
  -53,589
  -58,617
  -63,860
  -69,320
  -75,001
  -80,907
  -87,047

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  37
  57
  85
  124
  174
  240
  322
  422
  543
  686
  852
  1,042
  1,256
  1,494
  1,757
  2,044
  2,354
  2,688
  3,044
  3,423
  3,823
  4,244
  4,686
  5,149
  5,632
  6,136
  6,661
  7,207
  7,775
  8,365
Adjusted assets (=assets-cash), $m
  37
  57
  85
  124
  174
  240
  322
  422
  543
  686
  852
  1,042
  1,256
  1,494
  1,757
  2,044
  2,354
  2,688
  3,044
  3,423
  3,823
  4,244
  4,686
  5,149
  5,632
  6,136
  6,661
  7,207
  7,775
  8,365
Revenue / Adjusted assets
  0.162
  0.175
  0.176
  0.169
  0.172
  0.175
  0.174
  0.173
  0.175
  0.173
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
  0.174
Average production assets, $m
  5
  8
  11
  16
  23
  32
  43
  56
  72
  91
  113
  138
  166
  198
  233
  271
  312
  356
  403
  453
  506
  562
  620
  682
  746
  812
  882
  954
  1,029
  1,108
Working capital, $m
  -10
  -16
  -24
  -34
  -48
  -66
  -89
  -117
  -150
  -190
  -236
  -288
  -347
  -413
  -486
  -565
  -651
  -744
  -842
  -947
  -1,058
  -1,174
  -1,296
  -1,424
  -1,558
  -1,698
  -1,843
  -1,994
  -2,151
  -2,314
Total debt, $m
  7
  18
  33
  54
  81
  116
  160
  214
  278
  355
  444
  545
  660
  787
  928
  1,081
  1,247
  1,426
  1,616
  1,819
  2,033
  2,258
  2,495
  2,742
  3,001
  3,270
  3,551
  3,843
  4,147
  4,463
Total liabilities, $m
  20
  30
  46
  66
  93
  128
  172
  226
  291
  367
  456
  557
  672
  799
  940
  1,093
  1,260
  1,438
  1,629
  1,831
  2,045
  2,270
  2,507
  2,755
  3,013
  3,283
  3,564
  3,856
  4,159
  4,475
Total equity, $m
  17
  26
  40
  57
  81
  111
  150
  196
  253
  319
  396
  485
  584
  695
  817
  950
  1,095
  1,250
  1,416
  1,592
  1,778
  1,973
  2,179
  2,394
  2,619
  2,853
  3,097
  3,351
  3,615
  3,890
Total liabilities and equity, $m
  37
  56
  86
  123
  174
  239
  322
  422
  544
  686
  852
  1,042
  1,256
  1,494
  1,757
  2,043
  2,355
  2,688
  3,045
  3,423
  3,823
  4,243
  4,686
  5,149
  5,632
  6,136
  6,661
  7,207
  7,774
  8,365
Debt-to-equity ratio
  0.430
  0.690
  0.840
  0.940
  1.000
  1.040
  1.070
  1.090
  1.100
  1.110
  1.120
  1.130
  1.130
  1.130
  1.140
  1.140
  1.140
  1.140
  1.140
  1.140
  1.140
  1.140
  1.140
  1.150
  1.150
  1.150
  1.150
  1.150
  1.150
  1.150
Adjusted equity ratio
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465
  0.465

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -409
  -619
  -912
  -1,312
  -1,840
  -2,520
  -3,373
  -4,421
  -5,680
  -7,168
  -8,893
  -10,867
  -13,092
  -15,572
  -18,305
  -21,289
  -24,519
  -27,990
  -31,697
  -35,633
  -39,794
  -44,176
  -48,775
  -53,589
  -58,617
  -63,860
  -69,320
  -75,001
  -80,907
  -87,047
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  2
  2
  2
  3
  4
  4
  5
  6
  7
  8
  9
  10
  12
  13
  15
  17
  19
  21
  23
  25
  27
  29
  32
  34
  37
Funds from operations, $m
  -409
  -618
  -912
  -1,311
  -1,839
  -2,518
  -3,371
  -4,418
  -5,677
  -7,164
  -8,889
  -10,862
  -13,087
  -15,566
  -18,297
  -21,280
  -24,509
  -27,978
  -31,683
  -35,618
  -39,778
  -44,157
  -48,754
  -53,566
  -58,592
  -63,833
  -69,290
  -74,969
  -80,873
  -87,010
Change in working capital, $m
  -4
  -6
  -8
  -11
  -14
  -18
  -23
  -28
  -34
  -40
  -46
  -52
  -59
  -66
  -73
  -79
  -86
  -92
  -99
  -105
  -111
  -117
  -122
  -128
  -134
  -139
  -145
  -151
  -157
  -163
Cash from operations, $m
  -405
  -612
  -904
  -1,300
  -1,825
  -2,500
  -3,349
  -4,390
  -5,644
  -7,124
  -8,844
  -10,810
  -13,028
  -15,500
  -18,225
  -21,201
  -24,423
  -27,886
  -31,585
  -35,513
  -39,667
  -44,041
  -48,632
  -53,438
  -58,458
  -63,693
  -69,145
  -74,818
  -80,716
  -86,847
Maintenance CAPEX, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -32
  -34
New CAPEX, $m
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -13
  -16
  -19
  -22
  -25
  -28
  -32
  -35
  -38
  -41
  -44
  -47
  -50
  -53
  -56
  -59
  -61
  -64
  -67
  -69
  -72
  -75
  -78
Cash from investing activities, $m
  -2
  -3
  -4
  -5
  -8
  -10
  -12
  -14
  -18
  -21
  -25
  -29
  -33
  -38
  -42
  -46
  -50
  -54
  -59
  -63
  -68
  -73
  -78
  -82
  -87
  -92
  -96
  -101
  -107
  -112
Free cash flow, $m
  -407
  -615
  -908
  -1,306
  -1,832
  -2,510
  -3,360
  -4,405
  -5,662
  -7,146
  -8,869
  -10,838
  -13,061
  -15,537
  -18,266
  -21,246
  -24,473
  -27,940
  -31,644
  -35,577
  -39,735
  -44,114
  -48,709
  -53,520
  -58,545
  -63,785
  -69,242
  -74,920
  -80,823
  -86,959
Issuance/(repayment) of debt, $m
  7
  11
  15
  21
  27
  35
  44
  54
  65
  76
  89
  101
  114
  128
  141
  153
  166
  179
  191
  202
  214
  225
  236
  248
  259
  270
  281
  292
  304
  316
Issuance/(repurchase) of shares, $m
  416
  628
  926
  1,330
  1,864
  2,550
  3,411
  4,467
  5,737
  7,234
  8,970
  10,955
  13,192
  15,683
  18,427
  21,422
  24,663
  28,145
  31,862
  35,809
  39,980
  44,372
  48,980
  53,804
  58,841
  64,094
  69,564
  75,255
  81,172
  87,321
Cash from financing (excl. dividends), $m  
  423
  639
  941
  1,351
  1,891
  2,585
  3,455
  4,521
  5,802
  7,310
  9,059
  11,056
  13,306
  15,811
  18,568
  21,575
  24,829
  28,324
  32,053
  36,011
  40,194
  44,597
  49,216
  54,052
  59,100
  64,364
  69,845
  75,547
  81,476
  87,637
Total cash flow (excl. dividends), $m
  17
  24
  33
  45
  59
  76
  95
  116
  140
  165
  191
  218
  246
  274
  302
  329
  357
  383
  409
  435
  459
  484
  508
  532
  555
  579
  603
  627
  652
  678
Retained Cash Flow (-), $m
  -416
  -628
  -926
  -1,330
  -1,864
  -2,550
  -3,411
  -4,467
  -5,737
  -7,234
  -8,970
  -10,955
  -13,192
  -15,683
  -18,427
  -21,422
  -24,663
  -28,145
  -31,862
  -35,809
  -39,980
  -44,372
  -48,980
  -53,804
  -58,841
  -64,094
  -69,564
  -75,255
  -81,172
  -87,321
Prev. year cash balance distribution, $m
  34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -365
  -604
  -893
  -1,285
  -1,805
  -2,475
  -3,317
  -4,351
  -5,597
  -7,069
  -8,780
  -10,737
  -12,946
  -15,409
  -18,126
  -21,093
  -24,307
  -27,762
  -31,453
  -35,375
  -39,521
  -43,888
  -48,473
  -53,272
  -58,286
  -63,515
  -68,961
  -74,627
  -80,519
  -86,643
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -350
  -553
  -777
  -1,058
  -1,399
  -1,796
  -2,241
  -2,720
  -3,215
  -3,706
  -4,169
  -4,582
  -4,922
  -5,173
  -5,321
  -5,360
  -5,289
  -5,113
  -4,843
  -4,495
  -4,088
  -3,642
  -3,177
  -2,713
  -2,267
  -1,853
  -1,480
  -1,155
  -879
  -652
Current shareholders' claim on cash, %
  9.0
  0.8
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

FINANCIAL RATIOS  of  RedHill Biopharma ADR (RDHL)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

RDHL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the RDHL stock intrinsic value calculation we used $4.007 million for the last fiscal year's total revenue generated by RedHill Biopharma ADR. The default revenue input number comes from 0001 income statement of RedHill Biopharma ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our RDHL stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for RDHL is calculated based on our internal credit rating of RedHill Biopharma ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of RedHill Biopharma ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of RDHL stock the variable cost ratio is equal to 6075%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $26 million in the base year in the intrinsic value calculation for RDHL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for RedHill Biopharma ADR.

Corporate tax rate of 27% is the nominal tax rate for RedHill Biopharma ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the RDHL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for RDHL are equal to 76.1%.

Life of production assets of 72.7 years is the average useful life of capital assets used in RedHill Biopharma ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for RDHL is equal to -159%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $45.065 million for RedHill Biopharma ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 21.344 million for RedHill Biopharma ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of RedHill Biopharma ADR at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
MRK Merck&Co 74.84 33.05  str.sell
GSK GlaxoSmithKlin 40.41 350.10  str.buy

COMPANY NEWS

▶ Raleigh's RedHill Biopharma is $25 million richer   [Aug-14-18 02:21PM  American City Business Journals]
▶ Why Redhill Biopharma Ltd. Stock Is Soaring Today   [Jul-30-18 11:51AM  Motley Fool]
▶ Is RedHill's experimental Ebola treatment on FDA fast track?   [May-30-18 03:09PM  American City Business Journals]
▶ Durham pharma eyes potential approval of drug in roughly $5B market   [May-07-18 11:48AM  American City Business Journals]
▶ RedHill revenues up 31 percent in Q4   [Apr-09-18 02:10PM  American City Business Journals]
▶ RedHill teams with Mayo Clinic, MD Anderson on new cancer trial   [Dec-28-17 02:10PM  American City Business Journals]
▶ RedHill Biopharma Provides 2017 Year-End Business Update   [Dec-05-17 09:30AM  GlobeNewswire]
▶ RedHill grows revenue in third quarter, closes public offering   [Nov-15-17 08:45AM  American City Business Journals]
▶ RedHill lands new orphan drug designation, looks to grow commercial portfolio   [Oct-23-17 08:30AM  American City Business Journals]
▶ Is RedHill Biopharma Ltd (RDHL) Undervalued?   [Sep-15-17 12:01PM  Simply Wall St.]
▶ RedHill keen on growth makes another commercial play   [Aug-17-17 02:55PM  American City Business Journals]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.